13F-HR filed by EcoR1 Capital, LLC
EcoR1 Capital, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 17:04:53 UTC, with 36 holding rows worth $2,252,570,642.
- Accession
- 0000935836-26-000577
- Filer
- CIK 1587114
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 36 entries on the cover page, a total value of $2,252,570,642 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,252,570,642 with VALUE read as dollars as filed, 13F file number 028-16764. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ZYMEWORKS INC | 98985Y108 | COM | 22,970,388 | $608,485,578 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 7,880,094 | $396,053,524 | dollars as filed | |
| Bristol-Myers Squibb Company | 110122108 | COM | 3,500,000 | $218,400,000 | dollars as filed | call |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 1,871,892 | $132,698,424 | dollars as filed | |
| ETON PHARMACEUTICALS INC | 29772L108 | COMMON STOCK | 2,470,920 | $127,227,671 | dollars as filed | |
| FIRST TRACKS BIOTHERAPEUTICS | 337185102 | ORD SHS *A* | 3,174,519 | $112,504,953 | dollars as filed | |
| AKTIS ONCOLOGY INC | 01021M104 | COMMON STOCK | 4,824,469 | $93,932,411 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 1,389,276 | $76,854,748 | dollars as filed | |
| ALTO NEUROSCIENCE INC COM SHS | 02157Q109 | Stock | 2,232,000 | $56,982,960 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 1,667,119 | $49,430,078 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 2,950,000 | $43,247,000 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 3,028,116 | $40,788,723 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 1,271,342 | $35,368,734 | dollars as filed | |
| ATTOVIA THERAPEUTICS INC | 04987L102 | COM | 2,024,010 | $34,691,531 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 6,803,785 | $25,174,005 | dollars as filed | |
| ADARx Pharmaceuticals, Inc. | 00654F105 | Common Stock, par value $0.0001 per share | 1,150,000 | $22,931,000 | dollars as filed | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 835,000 | $21,710,000 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 789,500 | $21,292,815 | dollars as filed | |
| Electra Therapeutics, Inc. | 284825106 | Common Stock, $0.0001 par value per share | 1,700,000 | $19,125,000 | dollars as filed | |
| ATARA BIOTHERAPEUTICS INC | 046513206 | COM NEW | 1,552,000 | $13,192,000 | dollars as filed | |
| CAPRICOR THERAPEUTICS INC | 14070B309 | COMMON STOCK | 1,376,580 | $13,036,213 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 500,000 | $12,475,000 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 555,555 | $12,344,432 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 1,666,667 | $10,466,669 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 375,000 | $8,891,250 | dollars as filed | |
| Braveheart Bio Inc | 10567X101 | COM | 416,700 | $8,417,340 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 235,000 | $7,454,200 | dollars as filed | |
| EIKON THERAPEUTICS INC | 282564103 | COMMON STOCK | 855,634 | $6,879,297 | dollars as filed | |
| ELOXX PHARMACEUTICALS INC | 29014R301 | COM NEW | 400,000 | $6,124,000 | dollars as filed | |
| AARDVARK THERAPEUTICS INC | 002942100 | COM | 720,028 | $3,794,548 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 889,607 | $3,647,389 | dollars as filed | |
| TCGX ACQUISITION CORP | G8708J109 | COM | 250,000 | $3,127,500 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 679,715 | $2,827,614 | dollars as filed | |
| HELIX ACQUISITION CORP III | G4444S107 | USD CL A ORD SHS | 200,000 | $2,124,000 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 64,303 | $862,946 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 100 | $7,089 | dollars as filed | call |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000935836-26-000577 | this filing | 2026-11-16 |